Strategies to access biosynthetic novelty in bacterial genomes for drug discovery
METADATA ONLY
Loading...
Author / Producer
Date
2022-05
Publication Type
Review Article
ETH Bibliography
yes
Citations
Altmetric
METADATA ONLY
Data
Rights / License
Abstract
Bacteria provide a rich source of natural products with potential therapeutic applications, such as novel antibiotic classes or anticancer drugs. Bioactivity-guided screening of bacterial extracts and characterization of biosynthetic pathways for drug discovery is now complemented by the availability of large (meta)genomic collections, placing researchers into the postgenomic, big-data era. The progress in next-generation sequencing and the rise of powerful computational tools provide unprecedented insights into unexplored taxa, ecological niches and ‘biosynthetic dark matter’, revealing diverse and chemically distinct natural products in previously unstudied bacteria. In this Review, we discuss such sources of new chemical entities and the implications for drug discovery with a particular focus on the strategies that have emerged in recent years to identify and access novelty.
Permanent link
Publication status
published
External links
Editor
Book title
Journal / series
Volume
21 (5)
Pages / Article No.
359 - 378
Publisher
Nature
Event
Edition / version
Methods
Software
Geographic location
Date collected
Date created
Subject
Organisational unit
03980 - Piel, Jörn / Piel, Jörn
Notes
Funding
742739 - Tailored chemical complexity through evolution-inspired synthetic biology (EC)
185077 - Investigating and utilizing uncultivated bacteria as a rich resource of bioactive natural products (SNF)
167051 - Ecosystem- and genome-guided antibiotic discovery (SNF)
185077 - Investigating and utilizing uncultivated bacteria as a rich resource of bioactive natural products (SNF)
167051 - Ecosystem- and genome-guided antibiotic discovery (SNF)